EirGenix, Inc.

Quick facts

Phase 3 pipeline

• EG12014 · Oncology
  EG12014 is a monoclonal antibody targeting CD19.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• EirGenix, Inc. portfolio CI brief
• EirGenix, Inc. pipeline updates RSS